» Articles » PMID: 33729496

AMH Highly Correlates With Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve Independent of Age

Overview
Specialty Endocrinology
Date 2021 Mar 17
PMID 33729496
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Antimüllerian hormone (AMH) level is strongly associated with ovarian response in assisted reproductive technology (ART) cycles but is a poor predictor of live birth. It is unknown whether AMH is associated with cumulative live birth rates (CLBRs) in women with diminished ovarian reserve (DOR).

Objective: To examine the association between serum AMH and CLBR among women with DOR undergoing ART.

Methods: Retrospective analysis of Society for Assisted Reproductive Technology Clinic Outcome Reporting System database 2014-16. A total of 34 540 index retrieval cycles of women with AMH <1 ng/mL. The main outcome measure was cumulative live birth.

Results: A total of 34 540 (25.9%) cycles with AMH <1 ng/mL out of 133 442 autologous index retrieval cycles were analyzed. Cycles with preimplantation genetic testing or egg/embryo banking were excluded. Data were stratified according to AMH and, age and regression analysis of AMH and CLBR was performed for each age stratum. Multiple logistic regression demonstrated that AMH is an independent predictor of CLBR (odds ratio [OR] 1.39, 95% CI 1.18-1.64). Serum AMH was strongly associated with number of oocytes retrieved, embryos cryopreserved, mean number of cumulative embryos transferred, and percentage of cycles that had an embryo transfer. Linear regression analysis demonstrated that AMH highly correlated with CLBR in each age stratum.

Conclusion: Serum AMH is highly correlated with CLBR in women with DOR independent of age. The addition of AMH to current age-based prognostication counseling particularly in women with DOR would provide more informative and personalized CLBR prediction prior to ART.

Citing Articles

How to estimate the probability of a live birth after one or more complete IVF cycles? the development of a novel model in a single-center.

Kong X, Liu Z, Huang C, Hu X, Mo M, Zhang H BMC Pregnancy Childbirth. 2025; 25(1):86.

PMID: 39885409 PMC: 11780784. DOI: 10.1186/s12884-024-07017-6.


Identify high-risk DOR women ≤ 35 years old following assisted reproduction technology through cutoffs of anti-mullerian hormone and antral follicle counts.

Teng Y, Pan P, Liu C, Lin Y, Zhu X, Wu S Reprod Biol Endocrinol. 2024; 22(1):130.

PMID: 39456075 PMC: 11515411. DOI: 10.1186/s12958-024-01298-4.


Current Status of Ovarian and Endometrial Biomarkers in Predicting ART Outcomes.

Volovsky M, Seifer D J Clin Med. 2024; 13(13).

PMID: 38999305 PMC: 11242103. DOI: 10.3390/jcm13133739.


Association between anti-mullerian hormone and metabolic syndrome: insights from a prospective community-based study.

Amiri M, Mousavi M, Noroozzadeh M, Farahmand M, Azizi F, Ramezani Tehrani F BMC Endocr Disord. 2024; 24(1):97.

PMID: 38926704 PMC: 11210108. DOI: 10.1186/s12902-024-01627-z.


A heatmap for expected cumulative live birth rate in preimplantation genetic testing for monogenic disorders and chromosomal structural rearrangements.

Van Der Kelen A, Keymolen K, Cools W, De Vos A, Polsler L, De Vos M J Assist Reprod Genet. 2024; 41(7):1907-1915.

PMID: 38753088 PMC: 11263274. DOI: 10.1007/s10815-024-03141-6.